These cell lines included CCRF-CEM (IC50: 6.95 μg/mL), HL60 (IC50: 8.16 μg/mL), HL60AR (IC50: 11.22 μg/mL) and CEM/ADR5000 (IC50: 6.56 μg/mL) leukemia cell lines, MDA-MB231 (IC50: 4.17 μg/mL) and MDA-MB231/BCRP (IC50: 19.45 μg/mL) breast adenocarcinoma cell line, HCT116 p53+/+ (IC50: 4.64 μg/mL) and HCT116 p53−/− (IC50: 4.62 μg/mL) colon carcinoma cell line, U87MG (IC50: 13.48 μg/mL) and U87MG.ΔEGFR (IC50: 7.44 μg/mL) gliobastoma cell line, Hep-G2 (IC50: 16.07 μg/mL) hepatocarcinoma cell line and Mia Paca2 (IC50: 8.92 μg/mL) pancreatic cancer cell line (Kuete et al., 2011, 2013). This evidence concerns the gene TP53 and breast adenocarcinoma.